| Home : April 2011 : April 14, 2011 News : Debiopharm and Aurigene Sign Agreement for the Development and Commercialisation of Debio 1142, a Novel Inhibitor of an Undisclosed Oncology Pathway |
Debiopharm and Aurigene Sign Agreement for the Development and Commercialisation of Debio 1142, a Novel Inhibitor of an Undisclosed Oncology Pathway |
April 14, 2011
LAUSANNE, Switzerland and BANGALORE, India, April 14, 2011 /PRNewswire/
-- Debiopharm Group(TM) (Debiopharm), a global biopharmaceutical development
specialist that focuses on serious medical conditions and particularly
oncology, and Aurigene Discovery Technologies Ltd (Aurigene), a
Bangalore-ba
http://www.prnewswire.com/news-releases/debiopharm-and-aurigene-sign-agreement-for-the-development-and-commercialisation-of-debio-1142-a-novel-inhibitor-of-an-undisclosed-oncology-pathway-119827614.html
|
|
|
 Other Stories |
|
|
|
|
|
|
|
|
|
|
|
